Literature DB >> 20495085

Genetic/familial high-risk assessment: breast and ovarian.

Mary B Daly1, Jennifer E Axilbund, Saundra Buys, Beth Crawford, Carolyn D Farrell, Susan Friedman, Judy E Garber, Salil Goorha, Stephen B Gruber, Heather Hampel, Virginia Kaklamani, Wendy Kohlmann, Allison Kurian, Jennifer Litton, P Kelly Marcom, Robert Nussbaum, Kenneth Offit, Tuya Pal, Boris Pasche, Robert Pilarski, Gwen Reiser, Kristen Mahoney Shannon, Jeffrey R Smith, Elizabeth Swisher, Jeffrey N Weitzel.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20495085     DOI： 10.6004/jnccn.2010.0043

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


× No keyword cloud information.
  100 in total

1.  Bone loss after oophorectomy among high-risk women: an NRG oncology/gynecologic oncology group study.

Authors:  Elizabeth A Hibler; James Kauderer; Mark H Greene; Gustavo C Rodriguez; David S Alberts
Journal:  Menopause       Date:  2016-11       Impact factor: 2.953

2.  Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.

Authors:  Laura L Reimers; Parijatham S Sivasubramanian; Dawn Hershman; Mary Beth Terry; Heather Greenlee; Julie Campbell; Kevin Kalinsky; Matthew Maurer; Ramona Jayasena; Rossy Sandoval; Maria Alvarez; Katherine D Crew
Journal:  Breast J       Date:  2015-04-16       Impact factor: 2.431

3.  Unwrapping the implications of BRCA1 and BRCA2 mutations in ovarian cancer.

Authors:  David M Hyman; David R Spriggs
Journal:  JAMA       Date:  2012-01-25       Impact factor: 56.272

4.  Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer.

Authors:  Jada G Hamilton; Margaux C Genoff; Melissa Salerno; Kimberly Amoroso; Sherry R Boyar; Margaret Sheehan; Megan Harlan Fleischut; Beth Siegel; Angela G Arnold; Erin E Salo-Mullen; Jennifer L Hay; Kenneth Offit; Mark E Robson
Journal:  Breast Cancer Res Treat       Date:  2017-02-01       Impact factor: 4.872

5.  Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?

Authors:  Rachel Mitchell; Lela Buckingham; Melody Cobleigh; Jacob Rotmensch; Kelly Burgess; Lydia Usha
Journal:  PLoS One       Date:  2018-04-16       Impact factor: 3.240

Review 6.  Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting.

Authors:  Tuya Pal; Susan T Vadaparampil
Journal:  Cancer Control       Date:  2012-10       Impact factor: 3.302

7.  Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations.

Authors:  Joanne Ngeow; Kim Stanuch; Jessica L Mester; Jill S Barnholtz-Sloan; Charis Eng
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

8.  Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast Cancer.

Authors:  Carlos H Barcenas; Maryam N Shafaee; Arup K Sinha; Akshara Raghavendra; Babita Saigal; Rashmi K Murthy; Ashley H Woodson; Banu Arun
Journal:  J Natl Compr Canc Netw       Date:  2018-05       Impact factor: 11.908

9.  Reducing the Risk of Gynecologic Cancer in Hereditary Breast Ovarian Cancer Syndrome Mutation Carriers: Moral Dilemmas and the Principle of Double Effect.

Authors:  Murray Joseph Casey; Todd A Salzman
Journal:  Linacre Q       Date:  2018-07-20

10.  Utility of PTEN protein dosage in predicting for underlying germline PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypes.

Authors:  Joanne Ngeow; Xin He; Jessica L Mester; Junying Lei; Todd Romigh; Mohammed S Orloff; Mira Milas; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2012-10-12       Impact factor: 5.958
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.